Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 1.63 -4.12% -0.07
CTXR closed down 4.12 percent on Friday, October 19, 2018, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CTXR trend table...

Date Alert Name Type % Chg
Oct 19 Narrow Range Bar Range Contraction 0.00%
Oct 19 NR7 Range Contraction 0.00%
Oct 19 Strong but Oversold Other 0.00%
Oct 19 Strong, Oversold and Reversal Signs Reversal 0.00%
Oct 19 Oversold Stochastic Weakness 0.00%
Oct 18 20 DMA Resistance Bearish -4.12%
Oct 18 Stochastic Buy Signal Bullish -4.12%
Oct 18 Strong but Oversold Other -4.12%
Oct 18 Oversold Stochastic Weakness -4.12%
Oct 17 Strong but Oversold Other 0.62%

Older signals for CTXR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 1 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.49
52 Week Low 1.12
Average Volume 181,451
200-Day Moving Average 2.6432
50-Day Moving Average 1.5732
20-Day Moving Average 1.724
10-Day Moving Average 1.679
Average True Range 0.1699
ADX 25.76
+DI 24.7549
-DI 17.4669
Chandelier Exit (Long, 3 ATRs ) 2.0103
Chandelier Exit (Short, 3 ATRs ) 1.9597
Upper Bollinger Band 1.8721
Lower Bollinger Band 1.5759
Percent B (%b) 0.18
BandWidth 17.180974
MACD Line 0.0021
MACD Signal Line 0.0159
MACD Histogram -0.0138
Fundamentals Value
Market Cap 13.45 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.74
Resistance 3 (R3) 1.73 1.70 1.72
Resistance 2 (R2) 1.70 1.67 1.70 1.71
Resistance 1 (R1) 1.66 1.65 1.67 1.67 1.71
Pivot Point 1.63 1.63 1.63 1.63 1.63
Support 1 (S1) 1.59 1.60 1.60 1.60 1.55
Support 2 (S2) 1.56 1.58 1.56 1.55
Support 3 (S3) 1.52 1.56 1.54
Support 4 (S4) 1.53